# NEREUSTM (tradipitant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tradipitant

> The FDA approved NEREUSTM (tradipitant), sponsored by Vanda Pharmaceuticals Inc. (VNDA), on December 30, 2025 for vomiting induced.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is NEREUSTM (tradipitant) FDA approved?

Yes. The FDA approved NEREUSTM (tradipitant), sponsored by Vanda Pharmaceuticals Inc. (VNDA), on December 30, 2025 for vomiting induced. SEC Form 8-K: "On December 30, 2025, Vanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUSTM (tradipitant) for the prevention of vomiting induced by motion." [Calendar and source filings](https://sec-api.dev/pdufa/tradipitant)

Source: SEC Form 8-K, accession 0001628280-25-059155, https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda-20251230.htm (retrieved 2026-11-12). Last confirmed 2026-02-12. Cite: https://sec-api.dev/pdufa/tradipitant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | NEREUSTM (tradipitant) |
| Codes | VLY-686 |
| Sponsor | Vanda Pharmaceuticals Inc. (VNDA) https://sec-api.dev/companies/vnda/catalysts |
| Indications | [vomiting induced](https://sec-api.dev/indications/vomiting-induced), symptoms of gastroparesis to a final decision prior, [motion sickness](https://sec-api.dev/indications/motion-sickness), [Obesity](https://sec-api.dev/indications/obesity), Idiopathic Gastroparesis, Nausea and Vomiting |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2023: FDA approval

- Status: completed, approved. Date confidence: month. Indication: vomiting induced.
- First seen 2026-02-12, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "We have paid Lilly $5.0 million in upfront fees and development milestones, including a $2.0 million development milestone paid in December 2023 for the filing of the first marketing authorization for NEREUSTM in the U.S. or the E.U. In the fourth quarter of 2025, our NDA for the prevention of vomiting induced by motion was approved by the FDA and we accrued $10.0 million as a current liability as of December 31, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm

### Dec 2023: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In December 2023, the FDA accepted our NDA for NEREUSTM in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In December 2023, the FDA accepted our NDA for tradipitant in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### September 18, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-25-005761): "On September 18, 2024, we received a CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm
- SEC Form 10-K (accession 0001628280-26-007460): "On September 18, 2024, we received a CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-26-007460): "On September 18, 2024, we received a Complete Response Letter (CRL) from the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm

### September 18, 2024: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: symptoms of gastroparesis to a final decision prior.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In December 2023, the FDA accepted our NDA for NEREUSTM in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-26-007460): "In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for NEREUSTM for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-047317): "In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for tradipitant for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-036861): "In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for tradipitant for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for tradipitant for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In December 2023, the FDA accepted our NDA for tradipitant in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In September 2024, the Company filed a motion for a preliminary injunction to enjoin the FDA from subjecting the Company's NDA for tradipitant for the treatment of symptoms of gastroparesis to a final decision prior to the PDUFA target date of September 18, 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "On September 18, 2024, we received a CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### January 7, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-05-08, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001347178-26-000002): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-053855): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-031667): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828026031667/vnda-20260331.htm
- SEC Form 10-K (accession 0001628280-26-007460): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-Q (accession 0001628280-25-047317): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for tradipitant in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-036861): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for tradipitant in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for tradipitant in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm

### Apr 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-05-08, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001628280-25-047317): "In April 2025, the Company filed a motion for summary judgment regarding its motion sickness NDA and requested to file summary judgment regarding its gastroparesis NDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm
- SEC Form 10-Q (accession 0001628280-25-036861): "In April 2025, the Company filed a motion for summary judgment regarding its motion sickness NDA and requested to file summary judgment regarding its gastroparesis NDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm
- SEC Form 10-Q (accession 0001628280-25-023448): "In April 2025, the Company filed a motion for summary judgment regarding its motion sickness NDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023448/vnda-20250331.htm

### October 6, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06804603 (A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT06804603

### December 30, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: motion sickness.
- First seen 2025-03-17, last confirmed 2025-12-04.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-055393): "Separately, the ongoing review of the pending, fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track, with a PDUFA target action date of December 30, 2025, positioning tradipitant as potentially the first new pharmacologic treatment for motion sickness in over 40 years." https://www.sec.gov/Archives/edgar/data/1347178/000162828025055393/vnda8-k1242025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-054225): "•Separately, FDA recently issued labeling comments, and labeling discussions have formally begun for the New Drug Application of tradipitant for the prevention of vomiting induced by motion (PDUFA target action date remains December 30, 2025)" https://www.sec.gov/Archives/edgar/data/1347178/000162828025054225/vnda8-k11282025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-054225): "Separately, review of the NDA for tradipitant for the prevention of vomiting induced by motion continues according to schedule, with an unchanged PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025054225/vnda8-k11282025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-047112): "•Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025" https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-047112): "•Tradipitant NDA for motion sickness is under review by the FDA with a PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-043489): "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the FDA's ability to conduct expedited re-reviews of the partial clinical hold on tradipitant for the treatment of motion sickness by November 26, 2025 and the sNDA for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026, the FDA's ability to complete its review of the NDA for tradipitant for the treatment of motion sickness by the existing PDUFA target action date of December 30, 2025, and the results of the FDA's review of the NDA for tradipitant for the treatment of gastroparesis." https://www.sec.gov/Archives/edgar/data/1347178/000162828025043489/vnda8-k1012025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-036843): "•Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025" https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda8-k7312025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-036843): "•Tradipitant NDA for motion sickness is under review by the FDA with a PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda8-k7312025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023154): "•Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025" https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023154): "•Tradipitant New Drug Application (NDA) for motion sickness accepted for filing by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023154): "•The NDA for tradipitant for the treatment of motion sickness was accepted for filing by the FDA with a PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm
- SEC Form 10-Q (accession 0001628280-25-047317): "•Tradipitant NDA for motion sickness is under review by the FDA with a PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm

### December 30, 2025: NDA/BLA acceptance

- Status: scheduled. Date confidence: exact. Indication: motion sickness.
- First seen 2025-05-07, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023154): "•The NDA for tradipitant for the treatment of motion sickness was accepted for filing by the FDA with a PDUFA target action date of December 30, 2025." https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm

### December 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: vomiting induced.
- First seen 2025-12-31, last confirmed 2026-02-12.
- SEC Form 8-K (accession 0001628280-25-059155): "On December 30, 2025, Vanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUSTM (tradipitant) for the prevention of vomiting induced by motion." https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda-20251230.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-059155): "WASHINGTON, Dec. 30, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion." https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda8-k12302025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-059155): "Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness" https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda8-k12302025exhibit991.htm
- SEC Form 10-K (accession 0001628280-26-007460): "In December 2025, the Company announced that the FDA had approved the NDA for NEREUSTM." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm

### March 30, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06836557 (Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT06836557

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Nausea and Vomiting; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT07446439

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Nausea and Vomiting; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT07446439

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Motion Sickness.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06138613 (Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT06138613

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Motion Sickness.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06138613 (Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." https://clinicaltrials.gov/study/NCT06138613

## Same indication

- [ABBV-295](https://sec-api.dev/pdufa/abbv-295) (ABBV)
- [AZD6234](https://sec-api.dev/pdufa/azd6234) (AZN)
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide) (PFE)
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide) (NVO)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide) (LLY)
- [KAI-7535](https://sec-api.dev/pdufa/kai-7535) (KLRA)
- [LY3549492](https://sec-api.dev/pdufa/ly3549492) (LLY)
- [LY4086940](https://sec-api.dev/pdufa/ly4086940) (LLY)
- [Macupatide](https://sec-api.dev/pdufa/macupatide) (LLY)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Met097 injection](https://sec-api.dev/pdufa/met097) (PFE)
- [Nimacimab](https://sec-api.dev/pdufa/nimacimab) (SKYE)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016) (PFE)
- [PF-08653944](https://sec-api.dev/pdufa/pf-08653944) (PFE)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Ribupatide](https://sec-api.dev/pdufa/ribupatide) (KLRA)
- [IMCIVREE® (setmelanotide)](https://sec-api.dev/pdufa/setmelanotide) (RYTM)
- [Taldefgrobep alfa](https://sec-api.dev/pdufa/taldefgrobep-alfa) (BHVN)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a) (REGN)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)

Calendar months: [December 2025](https://sec-api.dev/fda-calendar/2025-12), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tradipitant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NEREUSTM (tradipitant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tradipitant

```bibtex
@misc{secapidev_pdufa_tradipitant_20261116,
  title        = {NEREUSTM (tradipitant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tradipitant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tradipitant_20261116","title":"NEREUSTM (tradipitant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tradipitant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
